Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens.
Hwang MS, Miller MS, Thirawatananond P, Douglass J, Wright KM, Hsiue EH, Mog BJ, Aytenfisu TY, Murphy MB, Aitana Azurmendi P, Skora AD, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Bettegowda C, Pardoll DM, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB. Hwang MS, et al. Among authors: dinapoli sr. Nat Commun. 2021 Sep 6;12(1):5271. doi: 10.1038/s41467-021-25605-4. Nat Commun. 2021. PMID: 34489470 Free PMC article.
Bispecific antibodies targeting mutant RAS neoantigens.
Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, Liu Q, Watson E, Li Y, Murphy MB, Pardoll DM, Bettegowda C, Papadopoulos N, Gabelli SB, Kinzler KW, Vogelstein B, Zhou S. Douglass J, et al. Among authors: dinapoli sr. Sci Immunol. 2021 Mar 1;6(57):eabd5515. doi: 10.1126/sciimmunol.abd5515. Sci Immunol. 2021. PMID: 33649101 Free PMC article.
Targeting a neoantigen derived from a common TP53 mutation.
Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, Schaefer A, Miller MS, Skora AD, Azurmendi PA, Murphy MB, Liu Q, Watson E, Li Y, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gabelli SB, Zhou S. Hsiue EH, et al. Among authors: dinapoli sr. Science. 2021 Mar 5;371(6533):eabc8697. doi: 10.1126/science.abc8697. Epub 2021 Mar 1. Science. 2021. PMID: 33649166 Free PMC article.
TCR β chain-directed bispecific antibodies for the treatment of T cell cancers.
Paul S, Pearlman AH, Douglass J, Mog BJ, Hsiue EH, Hwang MS, DiNapoli SR, Konig MF, Brown PA, Wright KM, Sur S, Gabelli SB, Li Y, Ghiaur G, Pardoll DM, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Vogelstein B. Paul S, et al. Among authors: dinapoli sr. Sci Transl Med. 2021 Mar 10;13(584):eabd3595. doi: 10.1126/scitranslmed.abd3595. Epub 2021 Mar 1. Sci Transl Med. 2021. PMID: 33649188 Free PMC article.
Targeting loss of heterozygosity for cancer-specific immunotherapy.
Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, Paul S, DiNapoli SR, Konig MF, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Vogelstein B, Zhou S, Kinzler KW. Hwang MS, et al. Among authors: dinapoli sr. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2022410118. doi: 10.1073/pnas.2022410118. Proc Natl Acad Sci U S A. 2021. PMID: 33731480 Free PMC article.
Targeting public neoantigens for cancer immunotherapy.
Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Pearlman AH, et al. Among authors: dinapoli sr. Nat Cancer. 2021 May;2(5):487-497. doi: 10.1038/s43018-021-00210-y. Epub 2021 May 17. Nat Cancer. 2021. PMID: 34676374 Free PMC article. Review.
Author Correction: Targeting public neoantigens for cancer immunotherapy.
Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Pearlman AH, et al. Among authors: dinapoli sr. Nat Cancer. 2021 Aug;2(8):865-867. doi: 10.1038/s43018-021-00246-0. Nat Cancer. 2021. PMID: 35122030 Free PMC article. No abstract available.
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Wright KM, DiNapoli SR, Miller MS, Aitana Azurmendi P, Zhao X, Yu Z, Chakrabarti M, Shi W, Douglass J, Hwang MS, Hsiue EH, Mog BJ, Pearlman AH, Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB. Wright KM, et al. Among authors: dinapoli sr. Nat Commun. 2023 Aug 21;14(1):5063. doi: 10.1038/s41467-023-40821-w. Nat Commun. 2023. PMID: 37604828 Free PMC article.
18 results